ISR News and Press, IsoRay Inc. From 04/29/22

RICHLAND, Wash., April 29, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the third quarter fiscal 2022 ended March 31,...

RICHLAND, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy, today announced that Chief Executive Officer Lori Woods will participate in a virtual fireside chat at the Oppenheimer 32 nd A...

RICHLAND, Wash., March 02, 2022 (GLOBE NEWSWIRE) -- Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 b...

Isoray, Inc. (ISR) Q2 2022 Earnings Conference Call Feb 08, 2022, 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mike Ott - Oppenheimer Tim Chiang - Northland Capital Kyle Krueger ...

IsoRay press release (NYSE:ISR): Q2 GAAP EPS of -$0.01 in-line. Revenue of $2.82M (+19.5% Y/Y) beats by $0.02M. Shares -0.39%. Gross profit as a percentage of revenues was 43.3% for the three months ended December 31, 2021 versus 49.5% in the prior year comparable period.  Cash, cash equ...

Revenue Increased 19% Year-Over-Year Prostate Brachytherapy Revenue Increased 13% Year-Over-Year RICHLAND, Wash., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its financia...

IsoRay (NYSE:ISR) is scheduled to announce Q2 earnings results on Tuesday, February 8th, after market close. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $2.8M For further details see: IsoRay Q2 2022 Earnings Preview

RICHLAND, Wash., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal 2022 ended December ...

Isoray, Inc. (ISR) Q1 2022 Earnings Conference Call November 10, 2021 04:30 p.m. ET Company Representatives Lori Woods - Chief Executive Officer Jonathan Hunt - Chief Financial Officer Mark Levin - Investor Relations Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mi...

IsoRay (NYSE:ISR): FQ1 GAAP EPS of -$0.02 misses by $0.01. Revenue of $2.56M (+7.6% Y/Y) beats by $0.06M. Press Release Isoray CEO Lori Woods said, “We are encouraged by the prospects for our core prostate brachytherapy business which grew year over year again this quarter. A...